Outcomes in COVID-19 ibrutinib studies

0 0.5 1 1.5+ All studies -9% 1 46 Improvement, Studies, Patients Relative Risk Mortality -9% 1 46 RCTs -9% 1 46 Late -9% 1 46 Ibrutinib for COVID-19 c19early.org November 2025 Favorsibrutinib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Woyach (RCT) unknown, >3 years late 10 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 study (+1 unreported RCT) c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] no disch. 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Woyach (RCT) unknown, >3 years late 10 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control iNSPIRE Coutre (DB RCT) -209% 3.09 [0.13-72.1] death 1/22 0/24 iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] no disch. 1/22 1/24 iNSPIRE Coutre (DB RCT) 35% 0.65 [0.18-2.42] progression 3/22 5/24 Ibrutinib COVID-19 outcomes c19early.org November 2025 Favors ibrutinib Favors control